Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain


Autoria(s): Camandaroba,Edson L.P.; Reis,Eliana A.G.; Gonçalves,Marilda S.; Reis,Mitermayer G.; Andrade,Sonia G.
Data(s)

01/04/2003

Resumo

The present investigation was performed to evaluate the susceptibility of seven clones isolated from the highly resistant Colombian strains, prototype of Biodeme Type III. Seven clones previously obtained, showed a phenotypic homogeneity and high similarity with the parental strain. Eight groups of 30 mice were inoculated with one of seven clones or the parental strain; 20 were treated with benznidazole (100mg/kg/day) and 10 were untreated controls. Cure evaluations were done by parasitological and serological tests and PCR. Cure rates varied from 0% (null) to 16.7%. Correlation between positivity of parasitological and serological tests with positive PCR reached 37%. The results demonstrated the high resistance of the clones, suggesting the predominance of a highly resistant principal clone in this strain. The findings apparently indicate that the possibility of cure is minimal for patients infected with this biodeme; a fact that could affect the control of Chagas' disease through treatment of chronically infected people.

Formato

text/html

Identificador

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822003000200002

Idioma(s)

en

Publicador

Sociedade Brasileira de Medicina Tropical - SBMT

Fonte

Revista da Sociedade Brasileira de Medicina Tropical v.36 n.2 2003

Palavras-Chave #Chagas' disease #Trypanosoma cruzi #Clones #Chemotherapy #Resistance #Benznidazole
Tipo

journal article